

- **Name:** Yoon Ji Choi
 - **Current Position & Affiliation:** Associate Professor, Division of Medical Oncology, Korea University College of Medicine
 - **Country:** Republic of Korea
-

- **Educational Background:**

2000-2006: M.D. Korea University College of Medicine, Seoul, Korea
 2008-2010: M.S. Internal Medicine, Korea University College of Medicine, Seoul, Korea
 2010-2015: Ph.D. Internal Medicine, Korea University College of Medicine, Seoul, Korea

- **Professional Experience:**

2006-2007: Internship, Korea University Medical Center, Seoul, Korea
 2007-2011: Residency in Internal Medicine, Korea University Medical Center, Seoul, Korea
 2011-2012: Clinical Fellowship, Division of Medical Oncology, Korea University Anam Hospital
 2012-2013: Clinical Fellowship, Department of Oncology, Asan Medical Center
 2013-2016: Clinical Assistant Professor, Division of Medical Oncology, Korea University Anam Hospital
 2016-2020: Assistant Professor, Division of Medical Oncology, Korea University Anam Hospital
 2020-current: Associate Professor, Division of Medical Oncology, Korea University Anam Hospital

- **Professional Organizations:**

Korean Society of Medical Oncology (KSMO)
 Korean Cancer Association (KCA)
 Korean Cancer Study Group (KCSG)
 Active member of Genitourinary Cancer & Lung Cancer Committee of KCSG
 American Society for Clinical Oncology (ASCO)
 American Association for Cancer Research (AACR)
 International Association for the Study of Lung Cancer (IASLC)

- **Main Scientific Publications:**

1. Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program. Park KH, Choi JY, Lim AR, Kim JW, Choi YJ, Lee S, Sung JS, Chung H-J, Jang B, Yoon D, S JK, Kim YH. *Cancer Discov.* 2022;12(4):938-948.
2. Comparison of the data of a next-generation sequencing panel from K-MASTER project with that of orthogonal methods for detecting targetable genetic alterations. Choi YJ, Choi JY, Kim JW, Lim AR, Lee Y, Chang WJ, Lee S, Sung JS, Chung H-J, Lee JW, Kang EJ, Kim JS, Lim T, Kim HS, Kim YJ, Ahn MS, Kim YS, Park JH, Lim S, Cho SS, Cho JH, Sin SW, Park KH, Kim YH. *Cancer Res Treat.* 2021 May. Online Ahead of print.
3. E-cigarette and cigarette use among cancer survivors versus general population: a case-control study in Korea. Paek J, Son S, Choi YJ. *J Cancer Surviv.* 2021 Jun 16. Online Ahead of print.
4. 2020 Korean guidelines for the management of metastatic prostate cancer. Kim I-H, Shin SJ,

- Kang BW, Kang J, Kim D, Kim M, Kim JY, Kim CK, Kim H-J, Maeng CH, Park K, Park I, Bae WK, Sohn BS, Lee M-Y, Lee JL, Lee J, Lim ST, Lim JH, Chang H, Jung JY, Choi YJ, Kim YS, Cho J, Joung JY, Park SH, Lee HJ. *Korean J Intern Med.* 2021 Feb 10
5. Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16). Byeon S, Kang MJ, Choi YJ, Kim YJ, Kim M, Yun J, Yi SY, Kim JY, Kim ST, Lee J. *Transl Cancer Res* 2020;9(5):3222-3230. (co-first)
 6. Impact of subsequent chemotherapy on the survival of elderly patients with extensive stage small cell lung cancer. Kang EJ, Choi YJ, Lee SR, Sung HJ, Kim JS. *Korean J Intern Med.* 2020 Nov;35(6):1468-1476 (co-first)
 7. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent osteoclastogenesis and breast cancer growth in the metastatic bone microenvironment. Kang J, Choi YJ, Seo BY, Jo U, Park SI, Kim YH, Park KH. *Sci Rep.* 2019 Jun 19;9(1):8726.
 8. Association between hand grip strength and impaired health-related quality of life in Korean cancer survivors: a cross-sectional study. Paek J, Choi YJ. *BMJ Open.* 2019 Sep 8;9(9):e030938.
 9. Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05). Choi YJ, Kim HS, Park SH, Kim B-S, Kim KH, Lee HJ, Song HS, Shin D-Y, Lee HY, Kim H-G, Lee KH, Lee JL, Park KH. *Cancer Res Treat.* 2018 Oct;50(4):1252-1259.
 10. A case report of primary pericardial malignant mesothelioma treated with pemetrexed and cisplatin. Kim JS, Lim SY, Hwang J, Kang EJ, Choi YJ. *J Korean Med Sci.* 2017;32:1879-1884.
 11. The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer. Choi YJ, Chang WJ, Shin SW, Park KH, Kim ST, Kim YJ. *Oncotargets and Therapy.* 2016;9:3307-3312.
 12. Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. Choi YJ, Lee DH, Choi CM, Lee JS, Lee SJ, Ahn J-H, Kim S-W. *BMC Cancer.* 2015;15:763.
 13. Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study. Choi YJ, Lee SH, Ahn J-H, Lee K-H, You D, Hong B, Hong JH, Ahn H. *Br J Cancer.* 2015;112:260-265.